Search Results - "Kiedrowski, Lesli A."

Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies by Odegaard, Justin I, Vincent, John J, Mortimer, Stefanie, Vowles, James V, Ulrich, Bryan C, Banks, Kimberly C, Fairclough, Stephen R, Zill, Oliver A, Sikora, Marcin, Mokhtari, Reza, Abdueva, Diana, Nagy, Rebecca J, Lee, Christine E, Kiedrowski, Lesli A, Paweletz, Cloud P, Eltoukhy, Helmy, Lanman, Richard B, Chudova, Darya I, Talasaz, AmirAli

“…To analytically and clinically validate a circulating cell-free tumor DNA sequencing test for comprehensive tumor genotyping and demonstrate its clinical…”
Get full text

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA by Agarwal, Neeraj, Pal, Sumanta K., Hahn, Andrew W., Nussenzveig, Roberto H., Pond, Gregory R., Gupta, Sumati V., Wang, Jue, Bilen, Mehmet A., Naik, Gurudatta, Ghatalia, Pooja, Hoimes, Christopher J., Gopalakrishnan, Dharmesh, Barata, Pedro C., Drakaki, Alexandra, Faltas, Bishoy M., Kiedrowski, Lesli A., Lanman, Richard B., Nagy, Rebecca J., Vogelzang, Nicholas J., Boucher, Kenneth M., Vaishampayan, Ulka N., Sonpavde, Guru, Grivas, Petros

“…BACKGROUND Biomarker‐guided clinical trials are increasingly common in metastatic urothelial carcinoma (mUC), yet patients for whom contemporary tumor tissue…”
Get full text

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors by Piccioni, David E, Achrol, Achal Singh, Kiedrowski, Lesli A, Banks, Kimberly C, Boucher, Najee, Barkhoudarian, Garni, Kelly, Daniel F, Juarez, Tiffany, Lanman, Richard B, Raymond, Victoria M, Nguyen, Minhdan, Truong, Judy D, Heng, Annie, Gill, Jaya, Saria, Marlon, Pingle, Sandeep C, Kesari, Santosh

“…Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate…”
Get full text

The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy by Jacob, Saya L., Kiedrowski, Lesli A., Chae, Young K.

“…Reversion mutations of somatic BRCA mutations are an important source of resistance within ovarian cancer. Furthermore, these reversion mutations are known to…”
Get full text

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer by Ezeife, Doreen A., Spackman, Eldon, Juergens, Rosalyn A., Laskin, Janessa J., Agulnik, Jason S., Hao, Desiree, Laurie, Scott A., Law, Jennifer H., Le, Lisa W., Kiedrowski, Lesli A., Melosky, Barbara, Shepherd, Frances A., Cohen, Victor, Wheatley-Price, Paul, Vandermeer, Rachel, Li, Janice J., Fernandes, Roxanne, Shokoohi, Aria, Lanman, Richard B., Leighl, Natasha B.

“…Background: Liquid biopsy (LB) can detect actionable genomic alterations in plasma circulating tumor circulating tumor DNA beyond tissue testing (TT) alone in…”
Get full text

Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA by Swami, Umang, Zimmerman, Raquel Mae, Nussenzveig, Roberto H, Hernandez, Edgar Javier, Jo, Yeonjung, Sayegh, Nicolas, Wesolowski, Sergiusz, Kiedrowski, Lesli A, Barata, Pedro C, Lemmon, Gordon Howard, Bilen, Mehmet A, Heath, Elisabeth I, Nandagopal, Lakshminarayan, Babiker, Hani M, Pal, Sumanta K, Lilly, Michael, Maughan, Benjamin L, Haaland, Benjamin, Yandell, Mark, Sartor, Oliver, Agarwal, Neeraj

“…-mutated prostate cancer has been shown to be less responsive to poly (ADP-ribose) polymerase (PARP) inhibitors as compared to -mutated prostate cancer. The…”
Get full text

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis by Dagogo-Jack, Ibiayi, Kiedrowski, Lesli A., Heist, Rebecca S., Lin, Jessica J., Meador, Catherine B., Krueger, Elizabeth A., Do, Andrew, Peterson, Jennifer, Sequist, Lecia V., Gainor, Justin F., Lennerz, Jochen K., Digumarthy, Subba R.

“…MET amplification is a potentially actionable resistance mechanism in ALK-rearranged (ALK+) lung cancer. Studies describing treatment outcomes of this…”
Get full text

Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic by Ghatalia, Pooja, Smith, Chad H, Winer, Arthur, Gou, Jiangtao, Kiedrowski, Lesli A, Slifker, Michael, Saltzberg, Patricia D, Bubes, Nicole, Anari, Fern M, Kasireddy, Vineela, Varshavsky, Asya, Liu, Yang, Ross, Eric A, El-Deiry, Wafik S

“…Liquid biopsy (LB) captures dynamic genomic alterations (alts) across metastatic colorectal cancer (mCRC) therapy and may complement tissue biopsy (TB). We…”
Get full text

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort by Fairclough, Stephen R, Kiedrowski, Lesli A, Lin, Jessica J, Zelichov, Ori, Tarcic, Gabi, Stinchcombe, Thomas E, Odegaard, Justin I, Lanman, Richard B, Shaw, Alice T, Nagy, Rebecca J

“…Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a…”
Get full text

Corrigendum: Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic by Ghatalia, Pooja, Smith, Chad H., Winer, Arthur, Gou, Jiangtao, Kiedrowski, Lesli A., Slifker, Michael, Saltzberg, Patricia D., Bubes, Nicole, Anari, Fern M., Kasireddy, Vineela, Varshavsky, Asya, Liu, Yang, Ross, Eric A., El-Deiry, Wafik S.

Get full text

Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma by Maron, Steven B, Chase, Leah M, Lomnicki, Samantha, Kochanny, Sara, Moore, Kelly L, Joshi, Smita S, Landron, Stacie, Johnson, Julie, Kiedrowski, Lesli A, Nagy, Rebecca J, Lanman, Richard B, Kim, Seung Tae, Lee, Jeeyun, Catenacci, Daniel V T

“…Gastroesophageal adenocarcinoma (GEA) has a poor prognosis and few therapeutic options. Utilizing a 73-gene plasma-based next-generation sequencing (NGS)…”
Get full text

Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition by Deng, Lei, Kiedrowski, Lesli A, Ravera, Elizabeth, Cheng, Haiying, Halmos, Balazs

Get more information

Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy by Dagogo-Jack, Ibiayi, Kiedrowski, Lesli A., Lennerz, Jochen K.

“…•High-level amplification is often observed in MET-amplified ALK + lung cancer.•MET-amplified ALK + lung cancer is enriched for TP53 mutations and MYC…”
Get full text

DNA Methylation Assay for X-Chromosome Inactivation in Female Human iPS Cells by Kiedrowski, Lesli A., Raca, Gordana, Laffin, Jennifer J., Nisler, Benjamin S., Leonhard, Kimberly, McIntire, Erik, Mongomery, Karen Dyer

“…Remarkable interest in the epigenetic status of human induced pluripotent stem (iPS) cells inspired numerous studies of their X-inactivation patterns. However,…”
Get full text

Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers by Kobayashi, Yoshihisa, Chhoeu, Chhayheng, Li, Jiaqi, Price, Kristin S., Kiedrowski, Lesli A., Hutchins, Jamie L., Hardin, Aaron I., Wei, Zihan, Hong, Fangxin, Bahcall, Magda, Gokhale, Prafulla C., Jänne, Pasi A.

“…RAS family members are the most frequently mutated oncogenes in human cancers. Although KRAS(G12C)-specific inhibitors show clinical activity in patients with…”
Get full text

The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib by Brown, Timothy J, Yablonovitch, Arielle, Till, Jacob E, Yen, Jennifer, Kiedrowski, Lesli A, Hood, Ryan, O'Hara, Mark H, Teitelbaum, Ursina, Karasic, Thomas B, Schneider, Charles, Carpenter, Erica L, Nathanson, Katherine, Domchek, Susan M, Reiss, Kim A

“…PARP inhibitors (PARPi) provide an effective maintenance option for patients with BRCA- or PALB2-mutated pancreatic cancer. However, mechanisms of PARPi…”
Get full text

Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion by Mortensen, Lindsey, Ordulu, Zehra, Dagogo‐Jack, Ibiayi, Bossuyt, Veerle, Winters, Loren, Taghian, Alphonse, Smith, Barbara L., Ellisen, Leif W., Kiedrowski, Lesli A., Lennerz, Jochen K., Bardia, Aditya, Spring, Laura M.

“…Enhanced understanding of the molecular events underlying oncogenesis has led to the development of “tumor‐agnostic” treatment strategies, which aim to target…”
Get full text

Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation by Schwartzberg, Lee S., Kiedrowski, Lesli A.

“…The oral poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib is approved for the treatment of patients with human epidermal growth factor…”
Get full text

Parents’ Perspectives on Variants of Uncertain Significance from Chromosome Microarray Analysis by Kiedrowski, Lesli A., Owens, Kailey M., Yashar, Beverly M., Schuette, Jane L.

“…Chromosomal microarray analysis (CMA) for unexplained anomalies and developmental delay has improved diagnosis rates, but results classified as variants of…”
Get full text

Use of on-therapy ctDNA monitoring in a patient with KIF5B-RET fusion positive advanced non-small cell lung cancer: a case report by Yeung, Vincent, Kim, Chul, Kiedrowski, Lesli A., Liu, Stephen V., Reuss, Joshua E.

“…Molecular characterization of non-small cell lung cancer (NSCLC) has led to marked improvements in the treatment of patients with advanced disease who harbor…”
Get full text